| Assessment Status |
NCPE assessment ongoing |
| HTA ID |
22061 |
| Drug |
Faricimab |
| Brand |
Vabysmo ® |
| Indication |
For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO). |
| Rapid review commissioned |
29/08/2022 |
| Rapid review completed |
04/10/2022 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab (Vabysmo®) for the treatment of DMO compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
25/10/2022 |
| Pre-submission consultation with Applicant |
03/10/2023 |
| Full submission received from Applicant |
12/06/2024 |
| Preliminary review sent to Applicant |
20/03/2025 |
| NCPE assessment re-commenced |
16/04/2025 |
